PubMed
Afamelanotide for erythropoietic protoporphyria
Langendonk et al., 2015
Sexual HealthCaution: Indication-Specific ApprovalS
Melanotan I
Afamelanotide-related
Alpha-MSH analog related to afamelanotide pathways; non-indicated tanning use carries risk.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 2
- Research grade
- S
- Community score
- 156
- Trackers
- 3,631
Trend index
Overview
About Melanotan I
Alpha-MSH analog related to afamelanotide pathways; non-indicated tanning use carries risk.
- Category
- Sexual Health
- Regulatory status
- Caution: Indication-Specific Approval
- Also known as
- Afamelanotide-related
- Self-reports
- 26
Community
What 26 users report
26 community reports
Positive 98% · Neutral 2% · Negative 0%
Most reported benefits
Libido
159
Mood
159
Most reported side effects
Nausea
2
Headache
1
Dose distribution
Median: 2000+ mcg · Most common: 2000+ mcg
0–25
0
25–50
0
50–100
0
100–200
0
200–400
2
400–600
12
600–1000
2
1000–2000
46
2000+
97
Commonly stacked with
How repeat users are trending
Among repeat reporters, 92% said they felt similar to their last entry, 8% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 127 days · Based on 25 repeat reporters
Research
Cited research (1)
Source
Help
Frequently asked
What do PeptIQ users report about Melanotan I?
This page summarizes 26 anonymized self-reports from PeptIQ users who track Melanotan I, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for Melanotan I?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Melanotan I safe to use?
This wiki does not assess safety or recommend use. Melanotan I is listed as Caution: Indication-Specific Approval. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Melanotan I?
Research, primarily in animal models, suggests Melanotan I may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Melanotan I?
Melanotan I is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Melanotan I as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Melanotan I?
The safety and effectiveness of Melanotan I have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Melanotan I?
While there are over 200 published studies on Melanotan I, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source